Tag Archives: atherogenesis

Two phase I studies with anacetrapib (Lancet 2007;370:1907–14), show impressive effects on raising high-density lipoprotein cholesterol (HDL-C)  and lowering low-density lipoprotein (LDL-C), with no signs of any increase in blood pressure. The authors, from Merck, US, conclude: “Anacetrapib seems to exhibit HDL-C increases greater than those seen with other investigational drugs in this class and LDL-C-lowering effects similar to statins. Despite greater lipid-altering effects relative to other members of this class, anacetrapib seems not to increase blood pressure, suggesting that potent CETP inhibition by itself might not lead to incre